QUOTE AND NEWS
Business Wire  May 8  Comment 
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Bank of
Market Intelligence Center  May 3  Comment 
ImmunoGen (NASDAQ: IMGN) closed Wednesday's trading session at $12.86. In the past year, the stock has hit a 52-week low of $9.17 and 52-week high of $16.20. ImmunoGen (IMGN) stock has been showing support around $12.23 and resistance in the...
Business Wire  Apr 27  Comment 
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period ended March
Market Intelligence Center  Apr 19  Comment 
ImmunoGen (NASDAQ:IMGN) closed Wednesday's deflating trading session at $12.22. In the past year, the stock has hit a 52-week low of $9.17 and 52-week high of $16.20. ImmunoGen (IMGN) stock has been showing support around $11.98 and resistance in...
Business Wire  Apr 18  Comment 
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 27, 2012, to discuss ImmunoGen's
Business Wire  Apr 17  Comment 
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that the Investigational New Drug (IND) application for its IMGN853 product candidate is now active. IMGN853 is a potential new
StreetInsider.com  Apr 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ImmunoGen+%28IMGN%29+Commences+IMGN529+Phase+I+in+Patients+with+NHL/7348500.html for the full story.
Business Wire  Apr 17  Comment 
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product
Market Intelligence Center  Apr 13  Comment 
ImmunoGen (NASDAQ:IMGN) closed Thursday's winning trading session at $12.97. In the past year, the stock has hit a 52-week low of $9.17 and 52-week high of $16.20. ImmunoGen (IMGN) stock has been showing support around $12.74 and resistance in the...
Market Intelligence Center  Apr 9  Comment 
ImmunoGen (NASDAQ:IMGN) closed Thursday's directionless trading session at $13.61. In the past year, the stock has hit a 52-week low of $9.17 and 52-week high of $16.20. ImmunoGen (IMGN) stock has been showing support around $13.12 and resistance...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki